Research Article| Volume 171, ISSUE 2, P235-239, December 2013

Download started.


Relationship between maternal antibody type and antenatal course following intrauterine transfusion for red cell alloimmunisation

Published:September 16, 2013DOI:



      To determine the antenatal course of severe red cell alloimmunisation in pregnancies requiring intrauterine fetal transfusion.

      Study design

      A retrospective cohort study over 16 years in a single national quaternary fetal medicine centre. From 1996 to 2011, 242 red cell intrauterine transfusions (IUT) were performed in 102 alloimmunised pregnancies. Antibody type was categorized into Rh(D) and non-Rh(D) (including Rh(c), Kell and Rh(E)). Women with Rh(D) antibodies were further stratified into those with and without additional red cell antibodies. Data were compared using the Mann–Whitney U and Fisher's exact tests. Two-tailed P values at the 5% level were considered significant.


      Comparing Rh(D) and non-Rh(D) pregnancies, there were no differences in either gestational age or fetal haemoglobin at first IUT, number of transfusions required, gestation at delivery, caesarean delivery rates or perinatal losses. In women sensitized to Rh(D), the presence of additional antibodies did not influence the degree of fetal anaemia or the first transfusion-delivery interval, although rates of fetal hydrops were higher in the presence of multiple antibodies. The “procedure-related” loss rate was 1.7% per procedure in our institution.


      Antibody status does not appear to influence clinical outcomes following fetal transfusion for alloimmunisation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Illanes S.
        • Soothill P.
        Noninvasive approach for the management of hemolytic disease of the fetus.
        Expert Rev Hematol. 2009; 2: 577-582
        • Moise Jr., K.J.
        • Argoti P.S.
        Management and prevention of red cell alloimmunisation in pregnancy: a systematic review.
        Obstet Gynecol. 2012; 120: 1132-1139
        • Bondagji N.S.
        Rhesus alloimmunisation in pregnancy: a tertiary care centre experience in the Western region of Saudi Arabia.
        Saudi Med J. 2011; 32: 1039-1045
        • Mari G.
        • Deter R.L.
        • Carpenter R.L.
        • et al.
        Noninvasive diagnosis by Doppler ultrasonography of fetal anaemia due to maternal red-cell alloimmunisation. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses.
        N Engl J Med. 2000; 342: 9-14
        • Oepkes D.
        • Seaward P.G.
        • Vandenbussche F.P.
        • et al.
        DIAMOND Study Group. Sonography versus amniocentesis to predict fetal anaemia.
        N Engl J Med. 2006; 355: 156-164
      1. ACOG Practice Bulletin No. 75: management of alloimmunisation during pregnancy.
        Obstet Gynecol. 2006; 108: 457-564
        • Van Kamp I.L.
        • Klumper F.J.
        • Oepkes D.
        • et al.
        Complications of intrauterine intravascular transfusion for fetal anaemia due to maternal red-cell alloimmunisation.
        Am J Obstet Gynecol. 2005; 192: 171-177
        • Oepkes D.
        • Adama van Scheltema P.
        Intrauterine fetal transfusions in the management of fetal anaemia and fetal thrombocytopenia.
        Semin Fetal Neonatal Med. 2007; 12: 432-438
        • Schonewille H.
        • Klumper F.J.
        • van de Watering L.M.
        • Kanhai H.H.
        • Brand A.
        High additional maternal red cell alloimmunisation after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus.
        Am J Obstet Gynecol. 2007; 196: e1-e6
        • Leduc L.
        • Moise Jr., K.J.
        • Carpenter Jr., R.J.
        • Cano L.E.
        Fetoplacental blood volume estimation in pregnancies with Rh alloimmunisation.
        Fetal Diagn Ther. 1990; 5: 138-146
        • Mahony R.
        • McKeating A.
        • Murphy T.
        • McAuliffe F.
        • O’Herlihy C.
        • Foley M.
        Appropriate antenatal corticosteroid use in women at risk for preterm birth before 34 weeks of gestation.
        Br J Obstet Gynaecol. 2010; 117: 963-967
        • Mujezinovic F.
        • Alfirevic Z.
        Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review.
        Obstet Gynecol. 2007; 110: 687-694
        • Moise K.J.
        Fetal anaemia due to non-Rhesus-D red-cell alloimmunisation.
        Semin Fetal Neonatal Med. 2008; 13: 207-214
        • Koelewijn J.M.
        • Vrijkotte T.G.
        • van der Schoot C.E.
        • Bonsel G.J.
        • de Haas M.
        Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
        Transfusion (Paris). 2008; 48: 941-952
        • Tiblad E.
        • Kublickas M.
        • Ajne G.
        • et al.
        Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunisation in Stockholm.
        Fetal Diagn Ther. 2011; 30: 266-273
        • Johnstone-Ayliffe C.
        • Prior T.
        • Ong C.
        • Regan F.
        • Kumar S.
        Early procedure-related complications of fetal blood sampling and intrauterine transfusion for fetal anaemia.
        Acta Obstet Gynecol Scand. 2012; 91: 458-462
        • Lindenburg I.
        • van Kamp I.
        • van Zwet E.
        • Middeldorp J.
        • Klumper F.
        • Oepkes D.
        Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation.
        Br J Obstet Gynaecol. 2013; 120: 847-852
        • Berkowitz R.L.
        • Beyth Y.
        • Sadovsky E.
        Death in utero due to Kell sensitization without excessive elevation of the delta OD450 value in amniotic fluid.
        Obstet Gynecol. 1982; 60: 746-749
        • McKenna D.S.
        • Nagaraja H.N.
        • O'Shaughnessy R.
        Management of pregnancies complicated by anti-Kell isoimmunization.
        Obstet Gynecol. 1999; 93: 667-673
        • Moise Jr., K.J.
        Non-anti-D antibodies in red-cell alloimmunisation.
        Eur J Obstet Gynecol Reprod Biol. 2000; 92: 75-81
        • Klumper F.J.
        • van Kamp I.L.
        • Vandenbussche F.P.
        • et al.
        Benefits and risks of fetal red-cell transfusion after 32 weeks gestation.
        Eur J Obstet Gynecol Reprod Biol. 2000; 92: 91-96
        • Spong C.Y.
        • Porter A.E.
        • Queenan J.T.
        Management of isoimmunization in the presence of multiple maternal antibodies.
        Am J Obstet Gynecol. 2001; 185: 481-484